News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
714,954 Results
Type
Article (44028)
Company Profile (440)
Press Release (670486)
Section
Business (209191)
Career Advice (2024)
Deals (36069)
Drug Delivery (102)
Drug Development (83818)
Employer Resources (171)
FDA (16536)
Job Trends (15122)
News (353713)
Policy (33175)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (11)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (6)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2691)
Accelerated approval (3)
Adcomms (24)
Allergies (80)
Alliances (51112)
ALS (83)
Alzheimer's disease (1382)
Antibody-drug conjugate (ADC) (114)
Approvals (16508)
Artificial intelligence (232)
Autoimmune disease (13)
Automation (14)
Bankruptcy (369)
Best Places to Work (11875)
BIOSECURE Act (18)
Biosimilars (96)
Biotechnology (334)
Bladder cancer (55)
Brain cancer (24)
Breast cancer (246)
Cancer (1885)
Cardiovascular disease (151)
Career advice (1688)
Career pathing (28)
CAR-T (139)
Cell therapy (404)
Cervical cancer (14)
Clinical research (67465)
Collaboration (759)
Compensation (424)
Complete response letters (23)
COVID-19 (2650)
CRISPR (38)
C-suite (202)
Cystic fibrosis (102)
Data (1803)
Decentralized trials (2)
Denatured (24)
Depression (45)
Diabetes (232)
Diagnostics (6412)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (115)
Drug pricing (103)
Drug shortages (26)
Duchenne muscular dystrophy (75)
Earnings (87177)
Editorial (34)
Employer branding (21)
Employer resources (147)
Events (115195)
Executive appointments (621)
FDA (17557)
Featured Employer (56)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (674)
Gene editing (98)
Generative AI (19)
Gene therapy (286)
GLP-1 (707)
Government (4471)
Grass and pollen (4)
Guidances (47)
Healthcare (19219)
Huntington's disease (23)
IgA nephropathy (23)
Immunology and inflammation (102)
Indications (25)
Infectious disease (2774)
Inflammatory bowel disease (135)
Inflation Reduction Act (11)
Influenza (44)
Intellectual property (74)
Interviews (312)
IPO (16785)
IRA (43)
Job creations (3711)
Job search strategy (1436)
Kidney cancer (9)
Labor market (29)
Layoffs (471)
Leadership (15)
Legal (7997)
Liver cancer (74)
Lung cancer (273)
Lymphoma (125)
Machine learning (2)
Management (58)
Manufacturing (262)
MASH (60)
Medical device (13580)
Medtech (13585)
Mergers & acquisitions (19707)
Metabolic disorders (629)
Multiple sclerosis (63)
NASH (19)
Neurodegenerative disease (82)
Neuropsychiatric disorders (29)
Neuroscience (1860)
NextGen: Class of 2025 (6798)
Non-profit (4568)
Northern California (2291)
Now hiring (36)
Obesity (349)
Opinion (217)
Ovarian cancer (63)
Pain (77)
Pancreatic cancer (72)
Parkinson's disease (128)
Partnered (17)
Patents (187)
Patient recruitment (85)
Peanut (46)
People (58467)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21199)
Phase II (29767)
Phase III (22001)
Pipeline (863)
Podcasts (68)
Policy (110)
Postmarket research (2613)
Preclinical (9065)
Press Release (67)
Prostate cancer (89)
Psychedelics (37)
Radiopharmaceuticals (259)
Rare diseases (365)
Real estate (6026)
Recruiting (66)
Regulatory (22602)
Reports (43)
Research institute (2448)
Resumes & cover letters (351)
Rett syndrome (3)
RNA editing (2)
RSV (37)
Schizophrenia (69)
Series A (122)
Series B (74)
Service/supplier (11)
Sickle cell disease (54)
Southern California (1988)
Special edition (17)
Sponsored (29)
Startups (3778)
State (2)
Stomach cancer (13)
Supply chain (59)
The Weekly (43)
United States (20506)
Vaccines (658)
Venture capitalists (36)
Webinars (13)
Weight loss (242)
Women's health (32)
Worklife (15)
Date
Today (119)
Last 7 days (610)
Last 30 days (3037)
Last 365 days (35137)
2025 (6539)
2024 (36403)
2023 (41156)
2022 (52412)
2021 (56889)
2020 (55065)
2019 (47638)
2018 (35878)
2017 (33228)
2016 (32628)
2015 (38678)
2014 (32434)
2013 (27488)
2012 (29565)
2011 (30148)
2010 (28259)
Location
Africa (741)
Alabama (53)
Alaska (7)
Arizona (225)
Arkansas (13)
Asia (39378)
Australia (6604)
California (5305)
Canada (1806)
China (433)
Colorado (244)
Connecticut (260)
Delaware (120)
Europe (86276)
Florida (772)
Georgia (180)
Idaho (57)
Illinois (488)
India (22)
Indiana (285)
Iowa (8)
Japan (132)
Kansas (103)
Kentucky (24)
Louisiana (8)
Maine (60)
Maryland (813)
Massachusetts (4086)
Michigan (207)
Minnesota (363)
Mississippi (2)
Missouri (73)
Montana (29)
Nebraska (25)
Nevada (54)
New Hampshire (65)
New Jersey (1508)
New Mexico (29)
New York (1503)
North Carolina (949)
North Dakota (7)
Northern California (2291)
Ohio (184)
Oklahoma (13)
Oregon (37)
Pennsylvania (1192)
Puerto Rico (6)
Rhode Island (25)
South America (1120)
South Carolina (16)
South Dakota (1)
Southern California (1988)
Tennessee (87)
Texas (783)
Utah (162)
Virginia (125)
Washington D.C. (58)
Washington State (515)
West Virginia (3)
Wisconsin (46)
714,954 Results for "tissue regeneration therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
FESARIUSTHERAPEUTICS INC ANNOUNCES FDA 510(K) CLEARANCE FOR DERMISPHERE HYDROGEL DERMAL REGENERATION TEMPLATE
January 8, 2025
·
3 min read
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
Axogen, Inc. announces the launch of its newest product, Avive+ Soft Tissue Matrix™. Avive+™ is intended for use as a soft tissue barrier and is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing.
June 24, 2024
·
6 min read
Press Releases
Data and Safety Monitoring Board Approves LyGenesis’s Phase 2a Clinical Trial to Continue and Dose Escalate in Novel Trial of Organ Regeneration
March 5, 2025
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Policy
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
FibroBiologics, Inc. announced the issuance of a patent from the Australian Patent Office covering the proprietary method using a particular cellular blend for the regeneration of chondrocytes or cartilage-type cells.
April 11, 2024
·
4 min read
Business
SoftWave Tissue Regeneration Technologies Receives Innovative Technology Contract From Vizient for DermaGold
SoftWave Tissue Regeneration Technologies announced its DermaGold an advanced wound care technology, has received an Innovative Technology contract from Vizient, Inc.
May 16, 2023
·
3 min read
Press Releases
Onco-Innovations’ Licensed Technology Shown in Study to Successfully Prevent Regeneration of Cancer Cells
January 17, 2025
·
5 min read
Drug Development
Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases
Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the publication of preclinical data in Molecular Therapy that further validates the therapeutic potential of ADX-097, a tissue-targeted complement inhibitor.
February 21, 2024
·
11 min read
Press Releases
Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics
January 8, 2025
·
3 min read
Press Releases
FDA Issues Draft Guidance on Including Tissue Biopsies in Clinical Trials
January 6, 2025
·
3 min read
1 of 71,496
Next
